/cloudfront-us-east-1.images.arcpublishing.com/abccolor/DJSN4X5YIBGHZLB6RZAS6575EI.jfif "The prestigious journal Vaccine has published a study on the Paraguayan vaccine against covid – National")
For the first time, a study on the phase III vaccine developed in Paraguay by professionals from the Faculty of Medical Sciences of the National University of Asunción and the Medigen Vaccine Biologics Corporation, is published by Revista Vaccine. This fact represents a real source of credit for the institution, since an article of this magnitude is made available to the entire international scientific community, through one of the most prestigious journals in the world of medicine.
Research presented and subsequently published by Vaccine magazinewas entitled “An Evaluation of the Safety and Immunogenicity of MVC-COV1901: results of an interim analysis of a study of PHASE IIIparallel group, randomized, double-blind, with active immunobridge control in Paraguay”.
The work was led by Professor Dr. Julio Torales, and had as co-authors the dean of Faculty of Medical Sciences of the UNA, master professor doctor Osmar Cuenca Torres; and medical professors Laurentino Barrios, Luis Armoa, Gladys Estigarribia, Gabriela Sanabria, Meei-Yun Lin; Josue Antonio Estrada, Lila Estephan, Hao-Yuan Cheng, Charles Chen, Rober Janssen and Chia-En Lien, of Medigen Vaccine Biologics of Taiwan.
She: To date, nearly 10 million vaccines against COVID-19 have been applied
For his part, Professor Dr. Julio Torales, principal investigator, highlighted that “this study demonstrates that our vaccine candidate is safe and immunogenic, and that it works against Covid-19, as well as demonstrating that as an institution, the A Faculty of Medical Sciences He has first-world investigative skills.”
What were the results?
Phase III vaccine trial MVC-COV1901carried out entirely in our country, lasting eight months included 1,030 randomized participants, concluded that a previous infection together with the application of this vaccine may offer protection against the Omicron strain, although its duration is still unknown.
She: Sequera: Pfizer vaccine “is good because it reduces the risk of hospitalization and death”
“Safety data was derived from this set, while the primary immunogenicity data was for a subset of the immunogenicity of protocol (PPI) which included 225 participants. Among the participants, 58% were HIV positive at the start of the study. Compared to AZD1222, MVC-COV1901 showed superiority in terms of neutralizing antibody titres and non-inferiority in terms of seroconversion rates,” explains the scientific article.
He adds that “The reactogenicity it was generally mild and no serious adverse events were attributed MVC-COV1901. Both vaccines have a Th1-biased response in which the production of the IgG1 and IgG3 subclasses predominates.
